Systemic treatment of hepatocellular carcinoma: Past, present and future

Table 2 Clinical trials with chemotherapy agents in hepatocellular carcinoma

Ref.	n	Treatment	Results
Lai et al[25]	60	Doxorubin vs placebo	OS 10.6 wk vs 7.5 wk in favour of chemo
Gish et al[27]		Doxorubicin vs nolatrexed	OS 32.3 wk vs 22.3 wk in favour of doxorubicin
Patt et al[35]	37	Capecitabine	RR 1%, OS 10.1 mo
Qin et al[44]	371	FOLFOX 4 vs doxorubicin	RR 8.15% vs 2.67%	All in favour of FOLFOX 4
			DCR 52.17% vs 31.55%
			PFS 2.93 m vs 1.7 m
			OS 6.4 m vs 4.97 m
Shin et al[45]		Cisplatin, Capecitabine and Doxorubicin	RR 26%
Lee et al[46]		Cisplatin/doxorubicin	RR 19%
Zaanan et al[48]	204	GEMOX	RR 22% DCR 66% PFS 4.5 m
			OS 11 m
Patrikidou et al[49]	40	GEMOX after antiangiogenics failed	Partial responses 20%
			Stable disease 46%
			OS 8.3 m
Yang et al[50]		Cisplatin/gemcitabine	RR 21%
Kim et al[52]		Cisplatin/infusional FU/mitoxantrone	RR 27% but 71% severe neutropenia

RR: Response rate; DCR: Disease control rate; PFS: Progression free survival; OS: Overall survival.